SCHEMBL396525

SCHEMBL396525

c1ccc(Nc2ccc3ccccc3n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.61
RAB9A P51151 5/20 0.59
KMT2A Q03164 3/20 0.59
KDM4E B2RXH2 2/20 0.59
MAPT P10636 2/20 0.59
MEN1 O00255 2/20 0.59
ALPG P10696 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
PDGFRB P09619 2/20 0.58
PDGFRA P16234 2/20 0.58
RHOA P61586 1/20 0.56
NPC1 O15118 3/20 0.51
ALDH1A1 P00352 3/20 0.51
NFKB1 P19838 2/20 0.51
NFKB2 Q00653 2/20 0.51
RELA Q04206 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
GAA P10253 1/20 0.51
DHFR P00374 2/20 0.49
CHEK1 O14757 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29833517 1.00 NCF1 (0.61) NCF1RAB9AKMT2AKDM4EMAPT
SCHEMBL30760998 0.87 NCF1 (0.71) NCF1RAB9AKMT2AKDM4ERHOA
SCHEMBL10458402 0.87 NCF1 (0.71) NCF1RAB9AKMT2AKDM4ERHOA
SCHEMBL1703350 0.86 NCF1 (0.55) NCF1RAB9AKMT2AKDM4EMAPT
SCHEMBL8564697 0.85 NCF1 (0.53) NCF1RAB9AKMT2AKDM4EMAPT
SCHEMBL29110577 0.85 NPC1 (0.58) NCF1RAB9AKMT2AKDM4EMAPT
SCHEMBL4494871 0.85 KMT2A (0.58) NCF1RAB9AKMT2AKDM4EMAPT
SCHEMBL12431347 0.85 NCF1 (0.58) NCF1RAB9AKMT2AKDM4EMAPT
SCHEMBL4812645 0.85 NCF1 (0.53) NCF1RAB9AKMT2AKDM4EMAPT
SCHEMBL1702296 0.84 SCN9A (0.52) NCF1RAB9AKMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136781-A ROR 1-targeted inhibitor and synthesis method and application thereof 北京大学 2025-06-13 CN claimed
CN-114907261-B 2-phenylaminoquinoline derivative, preparation method and application thereof 湖南中医药大学 2023-10-27 CN claimed
CN-114907261-A 2-phenylamino quinoline derivative and preparation method and application thereof 湖南中医药大学 2022-08-16 CN claimed
US-20190117683-A1 ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT ALGIPHARMA AS (NO) 2019-04-25 US claimed
US-20180055873-A1 USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION ALGIPHARMA AS (NO) 2018-03-01 US claimed
CN-107721923-A 4 N anilino quinolines class compound synthesis and the application for preparing anti-Alzheimer disease medicine 天津理工大学 2018-02-23 CN claimed
EP-3273995-A1 USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION ALGIPHARMA AS (NO) 2018-01-31 EP claimed
WO-2017060388-A1 ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT ALGIPHARMA AS (NO) 2017-04-13 WO claimed
WO-2016151051-A1 USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION ALGIPHARMA AS (NO) 2016-09-29 WO claimed
CN-101180273-A Methods of synthesizing 6-alkylaminoquinoline derivatives WYETH CORP (US) 2008-05-14 CN claimed
WO-2006127203-A2 METHODS OF SYNTHESIZING 6-ALKYLAMINOQUINOLINE DERIVATIVES WYETH (US) 2006-11-30 WO claimed
US-20060270670-A1 Methods of synthesizing 6-alkylaminoquinoline derivatives WYETH 2006-11-30 US claimed
US-5856337-A 2-arylquinolines and process for producing the same ASAHI GLASS CO., LTD. (JP) 1999-01-05 US claimed
EP-0786460-A2 2-Arylquinolines and process for producing the same ASAHI GLASS COMPANY LTD. (JP) 1997-07-30 EP claimed
EP-0291809-B1 2-ANILINO-QUINOLINES, PROCESSES FOR THEIR PREPARATION AND FUNGICIDES CONTAINING THEM BASF Aktiengesellschaft (DE) 1992-01-15 EP claimed
EP-0291809-A1 2-Anilino-quinolines, processes for their preparation and fungicides containing them BASF Aktiengesellschaft (DE) 1988-11-23 EP claimed
EP-0073875-B1 AZO DYESTUFFS, PROCESS FOR THEIR PREPARATION AND THEIR USE CASSELLA Aktiengesellschaft (DE) 1988-09-07 EP claimed
US-4420308-A Process for the production of reserve effects on polyester textiles and polyester/cellulose mixed fibre textiles: discharge printing with disperse azo dye with alkyl or alkoxy carbonyl, cyand and hydroxy phenyl group CASSELLA AKTIENGESELLSCHAFT (DE) 1983-12-13 US claimed
EP-0073875-A2 Azo dyestuffs, process for their preparation and their use CASSELLA Aktiengesellschaft (DE) 1983-03-16 EP claimed
EP-0073876-A1 Process for the production of reserve prints on polyester or polyester cellulose blended textiles CASSELLA Aktiengesellschaft (DE) 1983-03-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270670-A1 Methods of synthesizing 6-alkylaminoquinoline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RECQL, NQO2 NCF1 2378/4885RAB9A 1046/4885KMT2A 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.